Factors determining blood viscosity include hematocrit, erythrocyte aggregation, erythrocyte flexibility, 6 platelet aggregation and plasma viscosity. 7 Finally, blood viscosity varies inversely with the shear rate such that at lower flow rates, viscosity increases, and as the flow increases, blood viscosity is reduced. This property of blood is dependent upon blood viscosity factors, particularly erythrocyte flexibility and aggregation. 8 The influence of other factors on blood viscosity, such as the Fahreus effect, screening effect and the inversion phenomenon depend upon blood vessel diameter.
Blood Flow in the Macrocirculation
Blood flow through conductance vessels (i.e., diameters larger than 100 fi) has been classically, although imprecisely, described by the Hagen-Poiseuille equation, A P 77 r 4 8 Lri where Q is blood flow, P is the pressure gradient, r is vessel radius, L is vessel length, and r| is viscosity. This equation not only demonstrates the inverse relationship between blood flow and viscosity, but also suggests that the only variables which may be manipulated in the clinical setting to improve blood flow are the pressure gradient, vessel radius and viscosity. Unfortunately, the Hagen-Poiseuille equation describes the flow of Newtonian fluids and blood behaves in a non-Newtonian fashion with blood viscosity increasing as the shear rate decreases. Thus, the Hagen-Poiseuille equation does not precisely describe the relationship between blood flow and blood viscosity especially at low shear rates. 5 - 8 Under normal conditions in healthy individuals, the pressure gradient and radius of conductance vessels are the major determinants of cerebral blood flow. However, in areas of focal cerebral ischemia which have lost their capacity to pressure autoregulate 9 and, in which vessels radius is maximal, 10 the blood viscosity assumes great importance in the determination of cerebral perfusion.
Hematocrit is a major factor influencing blood viscosity" l2 and its importance increases as the shear rate decreases ( fig. 1 ). Clinically important is the observation that the steepest portion of the blood viscosityhematocrit curve occurs within physiologic ranges of hematocrit. This curve shifts to the left as the shear rate decreases. Thus, a reduction in hematocrit within the physiologic range (30-50%) reduces blood viscosity more profoundly at the lower shear rates representative of low flow states. also influences blood viscosity. The normally reversible aggregation of erythrocytes is dependent upon the shear rate and the surface characteristics of these cells, such as membrane structure, electrostatic forces, presence of macromolecules (particularly fibrinogen), as well as metabolic factors, such as osmolarity and blood pH.'• 8 -l3 Erythrocytes clump or aggregate as the shear rate decreases and disaggregate as the shear rate increases. With laminar blood flow, the largest erythrocyte aggregates occur axially in the central low shear areas, while disaggregation tends to occur in high shear regions along the vessel walls.
5 -8 -' 3 Blood viscosity is increased in proportion to the degree of erythrocyte aggregation.
Although erythrocyte flexibility is an important determinant of blood viscosity at any hematocrit in vessels of any radius, this factor relates more to the microcirculation. The low internal viscosity of the erythrocyte promotes great flexibility of its membrane which maintains blood in the fluid state, even at exceptionally high hematocrits. 13 Platelet aggregation affects blood viscosity and blood flow by two mechanisms: (a) platelet aggregates may precipitate intravascular coagulation and generate thrombus; and (b) platelet aggregates may obstruct arteriolar and capillary vessels. 1 Platelet aggregation, unlike erythrocyte aggregation, is generally irreversible. As erythrocyte aggregation increases, smaller platelet particles within the axial stream move to the outer laminae of flow where shear rates are highest. Platelets within these high shear laminae are exposed to injury and thereby increase their adhesiveness and aggregation. Thus, erythrocyte aggregation may secondarily exacerbate platelet aggregation, further increasing blood viscosity and decreasing blood flow.
Plasma viscosity is largely influenced by the presence of macromolecules such as fibrinogen and a-2-macroglobulin. 13 Elevated plasma fibrinogen concentrations in turn augment erythrocyte aggregation. 14 Although elevation plasma viscosity may influence blood flow through vessels at any radius, the hemorheologic contributions of plasma viscosity requires further study.
Blood Flow in the Microcirculation
By definition, cerebral microcirculation begins at the level of penetration of 30-70 /x diameter arterioles into the brain substance. Vessel size is gradually reduced to a precapillary arteriolar diameter of 14-25 /x with the smallest capillary diameter being approximately 4-6 /u. 15 The venules of the microcirculation tend to mirror the arterioles with respect to their diameter at a given cortical depth, gradually increasing in size until they exit the brain substance to become the conductance venous system within the subarachnoid space. 1 Studies of blood flow and viscosity within the microvasculature are more complex and have required capillary models. The Fahreus and Cindqvist 16 first described an apparent decrease in viscosity of blood flowing through tubes of progressively smaller diameter. This phenomenon, referred to as the Fahreus effect, partially accounted for the inaccuracy of the Hagen-Poiseuille equation to predict blood viscosity in capillary tubes of a diameter below 0.3 mm. 16 This blood viscosity reduction in small capillary tubes is postulated to be secondary to the observed reduction in hematocrit that occurred as the tube diameter decreased. 16 Dintenfass found that this reduction in blood viscosity ceases when the vessel diameter approaches 5-7 (x. and, with further vessel reductions, the observed viscosity increases. 17 This observation is termed the inversion phenomenon and the vessel radius at which this inversion occurs is defined as the critical radius. Thus, this reversal of the Fahreus effect occurs at a vessel diameter approaching the diameter of the erythrocyte. The Fahreus effect has been found to vary as a function of the feed hematocrit (the hematocrit of blood entering the capillary tube) and the flow velocity within the capillary. With constant flow, the Fahreus effect varies linearly with the feed hematocrit, however, at unsteady flow rates, the Fahreus effect is variable. 18 The Fahreus effect has also been found to be inversely proportional to the hematocrit in larger diameter tubes and independent of hematocrit in smaller tubes.
In addition, a screening effect which mechanically reduces the hematocrit as the erythrocytes enter into the ostia of capillary tubes whose diameter is less than 60 fi increases as the flow rate decreases. 19 This screening effect appears to be less influenced by tube hematocrit than the Fahreus effect.
Similar to that in conductance vessels, blood flow and viscosity in the microcirculation also vary with hematocrit, erythrocyte flexibility, platelet aggregation and plasma viscosity. 20 The exact hematocrit in the microcirculation is disputed. The hypothesis that the contribution of the erythrocyte to blood viscosity in the microcirculation is less significant than that observed in the systemic circulation is based upon studies observing that the hematocrit within the initial segment of capillary-sized tubes approaches a value approximately two-thirds that of the systemic hematocrit 20 and that the hematocrit ratio for brain and subarachnoid vessels is about 0.69. 21 However, Dintenfass found that the critical capillary radius at which the inversion phenomenon occurs is directly related to the capillary hematocrit.
5 Therefore, the relationship of blood flow and viscosity within the microcirculation with respect to hematocrit appears to be more complex than that observed in the conductance vessels and requires further investigation.
Erythrocyte aggregation may profoundly modify cerebral blood flow in the microcirculation. As opposed to the larger size of conductance vessels, the smaller diameter of the capillaries may undergo actual plugging or obstruction by sufficiently-sized erythrocyte aggregates. 5 Since erythrocyte aggregation is shearrate dependent, this aggregation may be enhanced within the microcirculation in ischemic regions where the blood flow and, consequently, the shear rates are depressed. This augmentation of erythrocyte aggregation would further increase blood viscosity and reduce blood flow, thus producing a vicious cycle. 22 Both the marked flexibility and low internal viscosity of the human erythrocyte are major determinants of blood flow in the microcirculation. 13 - 20 Experimental demonstrations of a critical radius as low as 2 /JL imply a remarkable deformability of normal erythrocytes under appropriate flow conditions. 5 This flexibility decreases with aging of the erythrocyte and the spleen functions to sequester these cells as they become more rigid, thus assuring that circulating erythrocytes are optimally suited to flow within the microcirculation. The aging processes, 6 as well as various hemoglobinopathies, decrease erythrocyte flexibility with potentially adverse effects on perfusion through the microcirculation.
Blood flow in the microcirculation is also affected by platelet aggregation. As platelet aggregates increase, the vessel radius at which the inversion phenomenon occurs also increases. 5 Platelets, having almost no flexibility, behave as rigid particles, thus producing an increase in blood viscosity in direct proportion to their concentration.
As in conductance vessels, normal and pathologic levels of plasma proteins, particularly fibrinogen, theoretically affect viscosity and blood flow in the microcirculation.
Hemorheology in Experimental Cerebral Ischemia
Pathologic alterations in the rheologic factors of blood may underlie or result from acute reductions in brain perfusion.
6 " 12 - 23 Experimental attempts have been made to favorably manipulate these factors to improve cerebral blood flow.
Ischemia secondary to either acute or progressive decreases in regional cerebral perfusion compromises neuronal activity and, subsequently, produce neurologic deficit. As the depth of ischemia increases, membrane pumps fail and neuronal death occurs. In focally ischemic regions, the gradient of shear rates within vessels is depressed as the blood flow slows distal to a narrowed or occluded segment of cerebral artery. A vicious cycle results as the elevated blood viscosity within the region of slow blood flow further compromises perfusion and ischemia deepens." The irreversibility of this neuronal insult is dependent upon both the depth and duration of the ischemia 24 as well as the ability of conductance vessels to provide adequate collateral circulation to maintain neuronal metabolism within the ischemic region. 25 Experimental studies have demonstrated significant elevations in regional cerebral blood flow in focallyischemic brain following the acute reduction of hematocrit employing hypervolemic infusions of autologous plasma or low-molecular-weight dextran. 26 " 28 In one animal study, the size of hemispheric infarction following distal internal carotid and proximal middle cerebral arterial clipping was decreased by 60% after the administration of two serial infusions of low-molecular-weight dextran, each equal to 20% of the total blood volume. 2627 Experimental demonstrations of significant elevations in regional cerebral blood flow in ischemic 26 but not in non-ischemic brain 29 imply that the effect of hypervolemic hemodilution on brain perfusion is greater in regions of low flow and may be related to infusion-induced alterations in blood viscosity. 30 This hypothesis is supported by experimentallydemonstrated inverse correlations between cerebral blood flow within ischemic regions and fresh blood viscosity at low shear rates following hypervolemic hemodilution with autologous plasma. 30 This inverse relationship between cerebral perfusion and fresh blood viscosity occurs following low-molecularweight dextran or autologous plasma infusions even in the absence of ischemia.
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Although the oxygen content of the blood is reduced as the hematocrit is decreased, the relative oxygen transport capacity has been calculated to increase as the hematocrit is lowered to approximately 30% 32 " (fig. 2) . Accordingly, the optimal hematocrit for the survival of critically-ill postoperative patients has been reported to be 33%. 34 Our own experimental studies have supported this concept by demonstrating a favorable inverse relationship between regional cortical oxygen transport and hematocrit in ischemic, but not in normal, brain after hypervolemic hemodilution to a mean hematocrit of 33% with autologous plasma. 35 Other experimental 36 and clinical 37 evaluations have calculated optimal oxygen transport to the brain to occur at hematocrit of 35% and 40-42%, respectively. Recently, the reduction of hematocrit by venesection has also been shown to elevate oxygen transport to the brain in patients with high hematocrits. 38 Contrarily, hyperexpansion of the intravascular volume without hemodilution does not appear to improve cerebral blood flow. Whole blood infusions administered to dogs with focal ischemia secondary to cerebral arterial occlusions do not elevate cortical blood flow within the area of focal ischemia in the presence of unaltered blood pressure, despite significant elevations in cardiac output. 39 In addition, no correlation was observed between cardiac output and cerebral blood flow following nonhemodilutional hypervolemia. Decreased velocity of blood flow through superficial cortical vessels and enhancement of cerebral infarction has been observed in animals transfused with packed erythrocytes. 40 This unfavorable influence of nonhemodilutional hypervolemia with secondary hemoconcentration has been attributed to elevations in blood viscosity and cellular aggregation.
In general, alterations in blood flow and viscosity resulting from manipulations of erythrocyte aggregation, erythrocyte deformability, platelet aggregation and plasma viscosity are experimentally underlined. One animal study has failed to observe a beneficial effect of lowering plasma fibrinogen levels on the magnitude of ischemic injury to the brain. 41 
Hemorheology in Clinical Cerebral Ischemia
Controlled clinical studies have demonstrated that patients with neurologic deficits secondary to cerebral ischemia and fbcally reduced cerebral blood flow have increased blood viscosity. 6 ' " • l 2 2 3 4 2 A direct correlation has been observed between elevated hematocrit levels (which are frequently greater than 50%) and cerebral infarction size in patients with occlusive cerebrovascular disease ( fig. 3) . 43 Negative correlations between either hematocrit or serum fibrinogen levels and cerebral blood flow have been demonstrated in stroke patients." Our clinical data has demonstrated that reductions of hematocrit within physiologic range in patients with ischemic cerebrovascular disease reduces blood viscosity more profoundly at low shear rates and that blood viscosity and hematocrit are directly related. 44 Shear rate is also an important determinant of blood viscosity in stroke patients. Although plasma fibrinogen decreases during hemodilution therapy, the reduction of hematocrit has a greater influence upon the decreases in blood viscosity. 44 The contribution of erythrocyte deformability to clinical cerebral ischemia 10 is disputed, since the finding of reductions in erythrocyte deformability in elderly stroke patients as compared to age-matched control patients found by one group 6 has not been verified by other investiga- tors. 45 Increased platelet aggregation has been observed in young stroke patients when compared to young control individuals. 46 Although numerous investigators have attempted to enhance cerebral perfusion by manipulating rheologic factors in the treatment of acute cerebral ischemia, most early retrospective studies which either supported 47 
"
50 or refuted 51 " 53 the beneficial effect of low-molecular-weight dextran infusions in the treatment of acute ischemic stroke were all compromised by various problems in design, methodology and assessment. 22 Subsequent prospective evaluations of low-molecularweight dextran or 5% serum albumin solutions in patients with ischemic stroke have demonstrated diffuse improvement in regional cerebral blood flow, as well as significant increases in mean power frequency or reductions in the slowing of the quantitative electroencephalogram. 3 54 The induced augmentation of regional cerebral perfusion correlated inversely with hematocrit 3 ( fig. 4 ). More recently, a prospective randomized clinical trial in Sweden has verified the beneficial effect of the acute reduction in hematocrit (via venesection and low-molecular-weight dextran infusions) on the neurologic deficit in patients with acute cerebral ischemia less than 48 hours in duration. 55 That study found 85% of 52 hemodiluted and 64% of 50 control patients improved in neurological scoring over the first 10 days. At 3 months of follow-up, both groups had similar mortality rates, however the surviving group of hemodiluted patients had 3 times fewer patients remaining in the hospital and 3.8 times fewer patients unable to walk than did the surviving group of control patients. Thus, hemodilution therapy improved the overall clinical outcome over the first 3 months. 55 Attempts at clinically manipulating rheologic factors other than hematocrit have thus far been limited in number. Infusions of hydroxyethyl starch, a synthetic plasma volume expander, have been reported in preliminary trials to decrease erythrocyte aggregation, but only at concentrations of greater than 4%. 56 Contrary to discouraging reports of the experimental lowering of serum fibrinogen levels, 41 a recent clinical trial employing pentoxifylline, an inhibitor of fibrinogen synthesis, found significant reductions in blood viscosity and in plasma fibrinogen concentration, as well as improved platelet disaggregation and erythrocyte filterability, in patients with cerebrovascular disease, treated for 6 weeks. 57 These pentoxifylline-treated patients experienced significantly fewer ischemic episodes than did control patients.
Current Application and Future Investigation
Presently, incremental venesection with intravascular volume replacement with colloid solutions (isovolemic hemodilution) is used to increase cerebral blood flow in patients after cerebral arterial bypass surgery during the period in which the anastomosis undergoes dilatation. 4 Isovolemic hemodilution may be useful in augmenting cerebral perfusion distal to an obstructed or a severely stenotic carotid artery in patients with acute cerebral infarcts who are waiting 3-6 weeks to undergo cerebral arterial bypass surgery or carotid endarterectomy. lution) with or without venesection appears applicable to the treatment of acute ischemic stroke in vascular territories having collateralization. 5558 At present, hypervolemic hemodilution is also used to increase cerebral blood flow in patients at-risk of ischemia during and after cerebral revascularization, 4 aneurysm surgery and gradual carotid artery ligation.
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Experience with hypervolemic hemodilution in the treatment of patients with vertebrobasilar ischemia is limited. Encouraging results have been observed in those patients with documented basilar artery stenosis; however, no improvement has occurred in patients with basilar artery occlusion (Wood JH, unpublished data). Since hypervolemic hemodilution elevates collateral perfusion to ischemic brain regions which have anatomic anastomoses between major vascular territories 26 -"•"° and since the augmented collateral flow is proportional to the degree of collateralization, hypervolemic hemodilution is not likely to benefit ischemia in poorly-collateralized brain regions supplied by occluded functional end-arteries. Therefore, ischemic patients with occluded lenticulostriate, thalamoperforate, or penetrating basilar arterial branches would not be considered good candidates for this type of rheologic treatment.
Based upon these experimental and clinical observations which suggest that acute reductions in hematocrit may favorably modify the course of acute cerebral ischemia, the necessity of a prospective, randomized clinical trial involving large numbers of patients emerges. Such an investigation would require accurate assessment of the nature of the cerebrovascular event and assure comparable control and treatment groups by excluding patients in whom hemodilution therapy is likely to be of no benefit such as those with intracerebral hemorrhage and increased intracranial pressure, as well as those with brainstem or lacunar infarctions. In patients with higher baseline hematocrits, venesection would be required in addition to the infusion of plasma volume expanding colloids, because infusion alone cannot rapidly or sufficiently reduce high hematocrits. 22 Pulmonary capillary wedge pressure monitoring in an intensive care unit setting is needed for patients with marginal cardiac reserve, to ensure effective and safe hemodilutional therapy. The goal of therapy in all patients is the rapid reduction of hematocrit to a level of approximately 33% as soon as possible following the onset of acute cerebral ischemia. Although all of the treated patients would be maximallyhemodiluted within safe limits, those patients whose baseline hematocrits were higher at the time of admission would be expected to experience greater augmentation in cerebral blood flow, and, possibly, be more apt to demonstrate neurologic improvement following hemodilution. Therefore, the statistical analyses should include stratifications based upon the hematocrit prior to treatment. One such protocol strategy 22 is presented in table 1. Our experience (Wood JH, Prats AR, unpublished data) suggests that hemodilution therapy that does not result in a hematocrit reduction of *CaIculated for average body weight but may require adjustment for extremes of body weight. tNote that Dextran-40 expands blood volume by 1.4 cc for every 1.0 cc infused. If 5% human serum albumin is employed as replacement infusion, then amount replaced is same as amount of blood removed.
$Note that maximum dose of Dextran-40 given must not exceed 1.5 gm/kg per day so as to avoid coagulation complications. Thus, maximum daily dose of 10% Dextran-40 is 15 cc/kg.
Abbreviations: CT = computed tomographic scan; ICP = intracranial pressure; PCWP = pulmonary capillary wedge pressure; CVP = central venous pressure; Dextran-40 = low-molecular-weight dextran.
Modified with permission from Wood JH, Kee DB Jr: Clinical rheology of stroke and hemodilution. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM (eds): Stroke: Pathophysiology, Diagnosis and Management. New York, ChurchillLivingstone, 1985 (in press) greater than 15% does not necessarily raise cerebral blood flow and therefore patients with acute cerebral ischemia and relatively low hematocrits (30-38%) may not be expected to improve after hemodilution therapy. Thus, the assessment of cerebral blood flow during hemodilution therapy is crucial in clinical trials of this hemorheologic therapy.
Duration of therapy will vary from a minimum of 72 hours to a maximum depending upon the ability to taper the patient from the infusion while maintaining the level of improvement obtained during the course of treatment. 58 Both short-term and long-term 52 -55 results will be necessary to adequately evaluate any difference between treated and untreated groups.
If further studies of appropriate patient populations support published preliminary experimental and clinical observations, hemorheological manipulation may offer a rapid and relatively simple approach to the treatment of acute ischemic neurologic deficit secondary to cerebral arterial stenosis, thrombosis, embolization or vasospasm. 1 In addition, such therapy should be used routinely to augment cerebral blood flow perioperatively in patients undergoing cerebral revascularization, 4 carotid endarterectomy, carotid ligation and aneurysm surgery.
